Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
AbbVie
Eli Lilly and Company
National Cancer Institute (NCI)
Jazz Pharmaceuticals
Bayer
Arcus Biosciences, Inc.
Eli Lilly and Company
SystImmune Inc.
Institut Paoli-Calmettes
Eli Lilly and Company
University of Michigan Rogel Cancer Center
ViroMissile, Inc.
Duke University
Essen Biotech
Baylor College of Medicine
Nanjing Sanhome Pharmaceutical, Co., Ltd.
SystImmune Inc.
Daiichi Sankyo
Takeda
Second Life Therapeutics
Novartis
Var2 Pharmaceuticals
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
Stella Pharma Corporation
Tempus AI
Immunitas Therapeutics
Actym Therapeutics, Inc.
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Cancer Research UK
Novita Pharmaceuticals, Inc.
NuCana plc
University of Virginia
Medicenna Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Tongji Hospital
Technische Universität Dresden
OncoC4, Inc.
Columbia University
Elevation Oncology
Kymab Limited
Stanford University
Cedars-Sinai Medical Center